http://www.onoterat.sesv
The equipment and device market for this patient group is a very important part of the US overall medical device market and a number of the major US players are servicing it, and obviously a large number of technology providers and suppliers rely on it for revenues. Through this agreement, Corline will join that group.

“We are very proud to have been chosen by a major US medical device manufacturer as technology licensor and supplier. It will make us work even harder to achieve our stretched goals, market-wise and with our technology innovation efforts. This relationship will help develop Corline as an organization in a highly positive way, but also shows potential customers around the world that our technology truly stands out compared to the alternatives. Many medical devices need surface treatment to increase their biocompatibility and, of course, we see this agreement as the start of something very exciting”, concludes CEO Henrik Nittmar.


About Corline and CHS

Corline is a biotechnology company based in Uppsala, Sweden, that develops, manufactures and distributes a proprietary patent protected heparin conjugate surface (CHS) that can be used both for medical devices and for Regenerative Medicine (cell therapy and tissue engineering). In 2008 the market for Regenerative Medicine totaled a 1.5 bn USD turnover, with a 90 % share being focused in the US. The US based market analysis company Life Science Intelligence, estimates the total potential to be over 100 bn USD.

CHS can be used to coat living cells and tissue without compromising their biological functions. CHS helps attenuate the local inflammation that is formed on and around grafts at transplantation, and promotes new blood vessels to grow more quickly to support the graft. For the patient, CHS potentially means better clinical outcome and a more rapid recovery from treatment.

Corline conducts pre-clinical and clinical studies within a number of cell and tissue therapy areas. These studies are a first step towards realizing the company’s vision of having its CHS platform technology widely used within the future Regenerative Medicine market. The CHS technology is protected by more than 20 granted and pending patents.

Corline is a privately held company, financially backed by members of the Crafoord family, primarily known for the development of Swedish medical device company Gambro (founded by Holger Crafoord), and Lars Sunnanväder, a well-known entrepreneur who has founded several medical device and biotechnology companies, e.g. heart/lung assist and coronary surgical device manufacturer Jostra, lung assist device manufacturer Novalung, Jotec, Jolife, Joline and other companies within this field.

For more information, please contact:

Henrik Nittmar, CEO
Tel. +46 (0)18 71 30 90
henrik.nittmar@corline.se
www.corline.com

Corline Systems AB
Box 956
715 09 Uppsala
SWEDEN

]]>http://www.onoterat.se//news/news_148_2010_06_22_corline_signs_exclusive_license_and_supply_agreement_with_major_us_medical_device_manufacturer.htmhttp://www.onoterat.se//news/news_148_2010_06_22_corline_signs_exclusive_license_and_supply_agreement_with_major_us_medical_device_manufacturer.htm